Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of "Moderate Buy" by Analysts

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) has earned an average recommendation of "Moderate Buy" from the ten brokerages that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $37.56.

A number of analysts have recently weighed in on the company. Royal Bank of Canada dropped their price objective on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. JMP Securities dropped their price objective on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 7th. HC Wainwright reissued a "buy" rating and set a $34.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. The Goldman Sachs Group dropped their price target on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $36.00 price target on shares of Viridian Therapeutics in a research note on Tuesday, May 20th.

Hedge Funds Weigh In On Viridian Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in VRDN. Barclays PLC increased its holdings in shares of Viridian Therapeutics by 113.1% during the third quarter. Barclays PLC now owns 125,397 shares of the company's stock valued at $2,851,000 after acquiring an additional 66,550 shares in the last quarter. Nuveen Asset Management LLC increased its holdings in shares of Viridian Therapeutics by 198.2% during the fourth quarter. Nuveen Asset Management LLC now owns 681,012 shares of the company's stock valued at $13,055,000 after acquiring an additional 452,627 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Viridian Therapeutics by 4.0% during the fourth quarter. Vanguard Group Inc. now owns 4,595,049 shares of the company's stock valued at $88,087,000 after acquiring an additional 174,952 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of Viridian Therapeutics by 3.3% during the fourth quarter. Principal Financial Group Inc. now owns 178,444 shares of the company's stock valued at $3,421,000 after acquiring an additional 5,634 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Viridian Therapeutics by 11.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 575,070 shares of the company's stock valued at $11,024,000 after acquiring an additional 58,857 shares in the last quarter.

Viridian Therapeutics Price Performance

NASDAQ VRDN traded up $0.21 on Thursday, reaching $15.88. 701,102 shares of the company's stock traded hands, compared to its average volume of 1,179,873. Viridian Therapeutics has a 12 month low of $9.90 and a 12 month high of $27.20. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. The stock has a 50-day simple moving average of $13.41 and a 200 day simple moving average of $16.05. The stock has a market cap of $1.30 billion, a PE ratio of -3.68 and a beta of 0.41.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.87) EPS for the quarter, beating analysts' consensus estimates of ($0.95) by $0.08. The business had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.16 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The firm's revenue was up .0% compared to the same quarter last year. As a group, research analysts predict that Viridian Therapeutics will post -4.03 earnings per share for the current year.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.